McKesson Corporation
MCK
$1105.04
+0.20%
McKesson Corporation is one of the three dominant U.S. pharmaceutical wholesalers, sourcing and distributing branded, generic, and specialty drugs to retail chains, independent pharmacies, hospitals, and healthcare providers, while also operating medical-surgical distribution and pharmacy technology businesses and a Canadian wholesale footprint. Alongside Cencora and Cardinal Health, McKesson controls more than 90% of the U.S. pharmaceutical wholesale market, giving it an oligopolistic position defined by enormous revenue scale, razor-thin margins, and deep distribution moats rather than pricing power. The current investor narrative centers on the durability of that distribution model after a strong fiscal Q2 2027 print (revenue up 7.6% year over year with broad-based segment strength and an earnings beat), management's raised guidance, and the company's aggressive capital return through buybacks. Attention is also focused on McKesson's move into higher-margin care settings, highlighted by the joint $32.05-per-share buyout of Option Care Health with CD&R, which extends the company beyond pure drug distribution into home and alternate-site infusion care.…
MCK
McKesson Corporation
$1105.04
Related headlines
Investment Opinion: Should I buy MCK Today?
Rating: Hold (with a constructive bias). McKesson is a high-quality oligopoly compounder executing well — 7.57% revenue growth to $110.96 billion, 17.4% EPS growth to $10.47, and $6.908 billion of trailing free cash flow — but at $1,102.81 the stock already sits at 95% of its 52-week range with a consensus average target of $1,144.29 implying only +3.8% upside, so the risk/reward is balanced rather than compelling. The 13 Buy / 3 Hold / 0 Sell consensus (recommendation mean 1.56) confirms the fundamentals are well understood; the debate is now purely about price.
Supporting evidence for holding rather than selling: the PEG ratio of 0.457 against a 22.4x trailing and 21.1x forward PE says growth is cheap relative to the multiple; gross margin expanded to 3.57% from 3.43% a year ago and operating margin to 1.45% from 1.42%, real operating leverage for a 1%-margin distributor; net income rose to $1.218 billion from $1.11 billion; and EV/EBITDA of 15.5x is in line with a mature, cash-generative distributor rather than stretched. The bull case is further supported by the specialty/oncology mix shift ($14.98 billion quarterly revenue) and the $32.05-per-share Option Care Health buyout with CD&R, which moves McKesson into higher-margin alternate-site infusion care.
What would change the rating: an upgrade to Buy requires either a pullback toward the $965 analyst low target (roughly -12.5%, which would restore meaningful upside to the $1,144 average) or evidence that Option Care integration and specialty mix lift gross margin durably above 3.6% while EPS growth holds near the 17% pace. A downgrade to Sell would follow a break below the $1,000 area on decelerating specialty growth, a gross margin reversal toward the 3.35% seen in Q1 2026, or multiple compression toward the 15.7x Q4 2026 level. Verdict: fairly valued to modestly rich relative to its own 15x-22x historical PE band and at the premium end of healthcare distribution — a quality business at a full price, best owned on weakness rather than chased at the high.
Sign up to view all
MCK 12-Month Price Forecast
McKesson is a fundamentally sound oligopoly distributor whose execution is not in question — revenue is growing 7.57%, EPS 17.4%, gross margin is expanding, and trailing free cash flow is $6.908 billion. The problem is that the market has already recognized all of this: the stock trades at 22.4x trailing earnings, near the top of its 15x-22x historical band and at 95% of its 52-week range, while the consensus target offers just +3.8% upside. The 0.457 PEG argues the premium is earned by growth, so the most likely path is a grind higher in line with earnings rather than a sharp re-rating or a de-rating. I would upgrade to bullish on a pullback toward the $965 analyst low target or on evidence that Option Care and specialty mix lift gross margin durably above 3.6%, and downgrade to bearish if specialty growth decelerates or the multiple compresses toward 15.7x.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on McKesson Corporation's 12-month outlook, with a consensus price target around $1144.29 and implied upside of +3.5% versus the current price.
Average Target
$1144.29
16 analysts
Implied Upside
+3.5%
vs. current price
Analyst Count
16
covering this stock
Price Range
$965 - $1260
Analyst target range
Coverage is solid with 14 analysts: 13 rate the stock Buy and 3 Hold, with zero Sells, producing a consensus recommendation of "buy" and a recommendation mean of 1.56 (where 1.0 is a strong buy). The average target price is $1,144.29, implying about +3.8% upside from the current $1,102.81, so despite the bullish ratings the consensus sees the stock as fairly valued after its run. The consensus leans clearly bullish on direction but cautious on near-term upside, consistent with the stock trading near its 52-week high. The target range runs from a low of $965.00 (about 12.5% below the current price) to a high of $1,260.00 (about 14.3% above), a spread of roughly 27% of the current price that signals meaningful disagreement about the pace of growth and multiple expansion. The high target likely assumes continued double-digit EPS growth, successful integration of the Option Care Health acquisition, and further specialty/oncology mix shift; the low target implies margin pressure, slower generic or specialty growth, or a de-rating from the current 22.4x PE. Institutional ratings show a stable, conviction-holding pattern rather than fresh upgrades: JP Morgan reiterated Overweight on November 10, UBS, Evercore ISI, Leerink, and TD Cowen reiterated Buy/Outperform after the November 5 earnings, while RBC Capital and Mizuho remain Sector Perform/Neutral, indicating the bull case is well understood and the debate is now about valuation rather than fundamentals.
Bulls vs Bears: MCK Investment Factors
The bull case currently has stronger evidence: revenue growth of 7.57%, gross margin expansion to 3.57%, 17.4% EPS growth, $6.908 billion in trailing free cash flow, and a PEG of 0.457 all point to a business executing well at a reasonable price. The bear case is not about fundamentals deteriorating but about price: the stock trades at 95% of its 52-week range, the average analyst target implies only +3.8% upside, and the 22.4x PE is at the top of its historical band, meaning the easy money from multiple re-rating has likely been made. The single most important tension is whether earnings growth alone can drive returns from here, or whether the market will demand a de-rating as the multiple compresses toward its historical midpoint. How the Option Care Health integration and specialty mix shift play out over the next four quarters is the factor most likely to resolve that debate, since it determines whether the premium multiple is justified by a structurally higher-growth business or is simply a cyclical peak.
Bullish
- Oligopoly moat with 90%+ share: McKesson, Cencora, and Cardinal Health control over 90% of U.S. pharmaceutical wholesale, a structure that has proven durable across cycles. Scale of $110.96 billion in quarterly revenue and $6.908 billion in trailing free cash flow is effectively unreplicable by new entrants, and the three-player dynamic limits destructive price competition.
- Earnings growth outpacing multiple: The PEG ratio of 0.457 against a 22.4x trailing PE and 21.1x forward PE implies the market is paying very little for growth. Q2 2027 EPS of $10.47 rose from $8.92 a year earlier, a 17.4% increase, while net income climbed from $1.11 billion to $1.218 billion, so earnings are compounding faster than the multiple.
- Margin expansion on top of volume growth: Gross margin improved to 3.57% in Q2 2027 from 3.43% a year earlier, and operating margin rose to 1.45% from 1.42%, while revenue grew 7.57% to $110.96 billion. For a 1%-margin distributor, a 14-basis-point gross margin gain is meaningful operating leverage, and the trend has been consistent from 3.35% in Q1 2026.
- Specialty and alternate-site mix shift: Oncology and Multispecialty already contributes $14.98 billion of quarterly revenue, and the joint $32.05-per-share buyout of Option Care Health with CD&R pushes McKesson into higher-margin home and alternate-site infusion care. This is a deliberate move away from pure low-margin drug distribution toward care settings with better economics.
Bearish
- Consensus sees almost no upside: The average analyst target of $1,144.29 implies only +3.8% upside from $1,102.81, and the stock already trades at roughly 95% of its 52-week range of $723.68 to $1,121.50. When 13 of 14 analysts are bullish but the average target is barely above the current price, the bull case is fully priced and the debate has shifted to valuation.
- Multiple near top of historical band: The 22.4x trailing PE sits at the upper end of the roughly 15x-22x band seen over recent years (15.7x in Q4 2026, 20.4x in Q2 2026, 21.3x in Q3 2026). With limited room for further re-rating, forward returns depend almost entirely on earnings delivery rather than multiple expansion.
- Razor-thin margins leave little cushion: Net margin is just 1.10% and operating margin 1.45%, so a small shift in generic drug pricing, reimbursement, or customer mix can swing earnings disproportionately. Quarterly free cash flow is highly seasonal, ranging from -$332 million in Q1 2027 to $2.947 billion in Q2 2027, and the current ratio of 0.854 reflects a working-capital-intensive model with limited liquidity buffer.
- Negative equity and buyback dependence: Debt-to-equity of -3.97 and ROE of -2.19 stem from years of buybacks, including $894 million repurchased in Q2 2027, which have driven book equity negative. Capital return is buyback-led with only a 0.36% dividend yield and 8% payout ratio, so shareholder returns depend on sustained free cash flow generation rather than a durable dividend.
MCK Technical Analysis
McKesson is in a powerful, sustained uptrend: the stock is up 30.3% over the past year and 44.9% over six months, and at $1,102.81 it trades at roughly 95% of its 52-week range of $723.68 to $1,121.50, just below the high. That positioning signals strong momentum rather than a value setup, though proximity to the top of the range also raises the risk of overextension and profit-taking. The stock has also materially outperformed the market, with relative strength of +18.0 percentage points versus SPY over one year and +42.9 points over six months. Recent momentum is accelerating rather than fading: the stock gained 12.9% in the past month and 26.9% over three months, well ahead of SPY's -2.26% and -2.83% over the same windows, producing relative strength of +15.2 and +29.7 points respectively. The one-year gain of 30.3% is being led by a steeper short-term move, a classic acceleration pattern rather than a divergence, and the latest session added another 2.39% on a close at the high end of the range. With a beta of just 0.279, McKesson is roughly 72% less volatile than the market, so these percentage moves reflect genuine idiosyncratic strength rather than high-beta amplification, which supports position sizing but also means the stock is not a market-hedge. Key technical reference points are the 52-week low of $723.68 as major support (about 34% below the current price) and the 52-week high of $1,121.50 as immediate resistance, only about 1.7% above the current price. A clean breakout above $1,121.50 would confirm the uptrend and likely invite momentum buyers, while a failure there could produce a pullback toward the $1,000 round-number area; the maximum drawdown of -27.17% shows the stock can correct sharply when sentiment shifts despite its low beta.
Beta
0.28
0.28x market volatility
Max Drawdown
-27.2%
Largest decline past year
52-Week Range
$724-$1122
Price range past year
Annual Return
+31.2%
Cumulative gain past year
| Period | MCK Return | S&P 500 |
|---|---|---|
| 1m | +10.0% | -3.0% |
| 3m | +27.1% | -3.6% |
| 6m | +46.4% | -0.2% |
| 1y | +31.2% | +10.1% |
| ytd | +34.2% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MCK Fundamental Analysis
Revenue is growing at a healthy clip for a distributor of this scale: fiscal Q2 2027 revenue reached $110.96 billion, up 7.57% year over year from $103.15 billion, and the sequential trend is constructive ($105.38 billion in Q1, $96.30 billion in the prior-year Q4). The North American Pharmaceutical segment dominates at $91.36 billion, with Oncology and Multispecialty at $14.98 billion, Medical-Surgical at $3.10 billion, and Prescription Technology Solutions at $1.52 billion, so overall growth is driven overwhelmingly by core drug distribution while oncology and specialty represent the higher-growth adjacencies. The 7.6% growth rate implies the investment case rests on volume, mix shift toward specialty, and bolt-on expansion rather than pricing, which is consistent with the Option Care Health transaction. Profitability is thin but improving: Q2 2027 net income was $1.218 billion on a 1.10% net margin, with gross margin of 3.57% and operating margin of 1.45%, up from 3.43% gross and 1.42% operating margin in the prior-year quarter. Gross margin has trended from 3.35% in Q1 2026 to 3.57% in Q2 2027, and quarterly net income rose from $1.11 billion a year ago to $1.218 billion, showing modest but real margin expansion on top of revenue growth. These are normal economics for pharmaceutical wholesale, where scale and working-capital efficiency matter more than percentage margins. Balance sheet and cash flow are the key watch items: free cash flow is $6.908 billion on a trailing basis, but quarterly FCF is highly seasonal (-$332 million in Q1 2027 versus $2.947 billion in Q2 2027), and the current ratio of 0.854 and quick ratio of 0.517 reflect the working-capital-intensive model. The reported debt-to-equity of -3.97 and ROE of -2.19 are artifacts of negative book equity from years of buybacks (including $894 million repurchased in Q2 2027), not distress; interest coverage of roughly 15x and a cash balance of $6.62 billion support that read. The dividend is minimal (0.36% yield, 8% payout ratio), so capital return is buyback-led and internal cash generation comfortably funds growth capex of $123 million in the quarter.
Quarterly Revenue
$111.0B
2026-09
Revenue YoY Growth
+7.6%
YoY Comparison
Gross Margin
3.6%
Latest Quarter
Free Cash Flow
$6.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MCK Overvalued?
Because McKesson is profitable (Q2 2027 net income of $1.218 billion), the PE ratio is the appropriate primary metric: the trailing PE is 22.4x versus a forward PE of 21.1x, a modest 6% compression that implies the market expects only modest earnings growth rather than a re-rating. The low absolute multiple reflects the low-margin distribution model, and the PEG ratio of 0.457 suggests the stock is inexpensive relative to its growth rate. On a sales basis the stock looks extremely cheap at a PS ratio of 0.265 and EV/Sales of 0.322, but that is a function of $110 billion-plus quarterly revenue rather than genuine undervaluation; EV/EBITDA of 15.5x is the more meaningful cross-check and sits in line with a mature, cash-generative distributor. Peer comparison data is limited in the provided inputs, but the 22.4x trailing PE and 15.5x EV/EBITDA are consistent with the premium end of large-cap healthcare distribution, and the 0.457 PEG and 21.1x forward PE argue the premium is supported by earnings growth rather than stretched. Against its own history, the current 22.4x trailing PE sits near the upper end of the roughly 15x-22x band seen over the past several years (15.7x in Q4 2026, 20.4x in Q2 2026, 21.3x in Q3 2026), while the PS ratio of 0.265 is distorted by the market-cap source discrepancy and is not comparable to the 0.85-1.10 historical range. The read is that the market is pricing in optimistic but not extreme expectations, with the historical PE band suggesting limited multiple expansion left and future returns dependent on earnings delivery.
PE
22.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~37x
vs. Industry Avg
26.2x
Industry PE ~26.2x*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the fragility of a 1.10% net margin and 1.45% operating margin business. A 14-basis-point gross margin improvement drove much of the recent earnings beat, but the same leverage works in reverse: a modest shift in generic drug pricing or customer mix could erase that gain. Free cash flow is highly seasonal, swinging from -$332 million in Q1 2027 to $2.947 billion in Q2 2027, and the current ratio of 0.854 with a quick ratio of 0.517 leaves limited liquidity cushion. Negative book equity from $894 million of Q2 2027 buybacks produces a debt-to-equity of -3.97 and ROE of -2.19, which are artifacts rather than distress but mean the balance sheet offers no equity buffer if cash generation disappoints.
Market and competitive risks are dominated by valuation compression. At 22.4x trailing and 21.1x forward earnings, the stock sits at the top of its 15x-22x historical band, so any slowdown in earnings growth would likely trigger multiple contraction on top of the earnings miss. Beta of 0.279 means the stock is roughly 72% less volatile than the market, which limits macro-driven downside but also means the recent 44.9% six-month gain reflects idiosyncratic momentum that can reverse independently of the market. Competition is intensifying: Cencora raised its 2026 EPS outlook on specialty strength and Cardinal Health expects 8-11% pharma segment profit growth in fiscal 2027, directly contesting the specialty and oncology niches McKesson is counting on for its mix shift.
Worst-case scenario: the Option Care Health integration stumbles, specialty growth decelerates, and the multiple compresses toward the 15.7x seen in Q4 2026 while earnings growth stalls. Applied to current earnings, that de-rating alone implies roughly a 30% decline, and the stock's maximum drawdown of -27.17% shows such corrections are realistic despite the low beta. A move to the 52-week low of $723.68 would represent a loss of about 34% from the current $1,102.81, while the analyst low target of $965.00 implies roughly 12.5% downside. The realistic adverse range is therefore -12.5% to -34%, with the lower end requiring both a fundamental miss and a sentiment shift.
FAQ
The most severe risk is valuation compression: at 22.4x trailing earnings near the top of its historical band, a de-rating toward the 15.7x Q4 2026 level could erase roughly 30% of value even without an earnings miss. Second is margin fragility — net margin of just 1.10% and operating margin of 1.45% mean a small shift in generic pricing or reimbursement can swing earnings disproportionately, and the recent beat leaned on a 14-basis-point gross margin gain that could reverse toward the 3.35% Q1 2026 level. Third is competitive pressure in specialty, where Cencora has raised its 2026 EPS outlook on specialty strength and Cardinal Health expects 8-11% pharma segment profit growth in fiscal 2027, directly contesting McKesson's targeted adjacencies. Fourth is company-specific integration risk from the $32.05-per-share Option Care Health buyout, plus a working-capital-intensive balance sheet with a 0.854 current ratio and highly seasonal free cash flow (-$332 million in Q1 2027 versus $2.947 billion in Q2 2027).
The 12-month forecast is split into three scenarios: a 55% probability base case of $1,060-$1,160, a 25% bull case of $1,180-$1,260, and a 20% bear case of $900-$965. The base case is most likely and assumes revenue growth holds near 7.57%, gross margin stays in the 3.5-3.6% range, consensus FY EPS of $82.58 is met, and the multiple stays pinned near 21-22x — producing a grind toward the $1,144.29 analyst average. The bull case requires a Q3 2027 beat with raised guidance, Option Care synergies, and gross margin above 3.6% to reach the $1,260 high target, while the bear case assumes specialty deceleration, margin reversal, and multiple compression toward 15.7x, landing near the $965 analyst low. The key assumption behind the most likely outcome is that earnings growth, not multiple expansion, drives returns from here.
MCK looks fairly valued to modestly rich on an absolute basis but reasonable relative to its growth. The trailing PE of 22.4x and forward PE of 21.1x sit near the top of the roughly 15x-22x band seen over recent years (15.7x in Q4 2026, 20.4x in Q2 2026, 21.3x in Q3 2026), leaving little room for further multiple expansion. The PS ratio of 0.265 and EV/Sales of 0.322 look optically cheap but are artifacts of $110 billion-plus quarterly revenue, so EV/EBITDA of 15.5x is the more meaningful cross-check and is in line with a mature, cash-generative distributor. The PEG of 0.457 argues the premium is earned by growth rather than stretched, and the market appears to be pricing in steady high-single-digit revenue growth, continued margin expansion, and successful specialty mix shift — optimistic but not extreme expectations.
From a risk/reward standpoint, MCK is a good business at a fair-to-full price rather than a compelling bargain. The consensus average target of $1,144.29 implies only about +3.8% upside from $1,102.81, and with 13 of 14 analysts rating it Buy and zero Sells, the fundamental story is well understood and largely priced in. The upside case rests on continued 17% EPS growth and a successful Option Care Health integration pushing toward the $1,260 high target (+14.3%), while the downside case is a multiple compression toward the 15.7x historical low that could take the stock to the $965 analyst low (-12.5%) or the $723.68 52-week low (-34%). Given the 0.457 PEG and 0.279 beta, it is a reasonable buy for long-term investors seeking low-volatility compounding who can tolerate limited near-term upside, but it is less attractive for buyers chasing the 44.9% six-month move at the top of the range. A pullback toward $1,000 or below would materially improve the risk/reward.
MCK is better suited to long-term holding than short-term trading. It is a mature, cash-generative distributor with a 0.279 beta (roughly 72% less volatile than the market), a minimal 0.36% dividend yield with an 8% payout ratio, and capital return driven by buybacks ($894 million repurchased in Q2 2027) rather than income — a profile that rewards patience rather than tactical trading. Earnings visibility is high given the oligopoly structure and 13 Buy ratings, but the stock is at 95% of its 52-week range after a 44.9% six-month gain, so near-term upside is limited and a pullback is plausible. A suggested minimum holding period is 12-18 months, long enough to capture at least two more earnings cycles and clarity on the Option Care integration, with entry on weakness toward $1,000 or below preferred over chasing the current high.

